Publication

Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

IRIDIUM trial investigators, Kerstjens, H. A. M., Maspero, J., Chapman, K. R., van Zyl-Smit, R. N., Hosoe, M., Tanase, A-M., Lavecchia, C., Pethe, A., Shu, X. & D'Andrea, P., 9-Jul-2020, In : The Lancet. Respiratory Medicine. 8, 10, p. 1000-1012 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • IRIDIUM manuscript_R2_2403_clean version

    Final author's version, 397 KB, PDF document

    Embargo ends: 09/07/2021

    Request copy

  • IRIDIUM study primary manuscript_tables_2403_clean version

    Final author's version, 229 KB, PDF document

    Embargo ends: 09/07/2021

    Request copy

  • Figure 1

    Final author's version, 597 KB, application/octet-stream

    Embargo ends: 09/07/2021

    Request copy

  • Figure 2a

    Final author's version, 611 KB, application/octet-stream

    Embargo ends: 09/07/2021

    Request copy

  • Figure 3a

    Final author's version, 610 KB, application/octet-stream

    Embargo ends: 09/07/2021

    Request copy

  • Figure 2b

    Final author's version, 822 KB, application/octet-stream

    Embargo ends: 09/07/2021

    Request copy

  • Figure 3B

    Final author's version, 608 KB, application/octet-stream

    Embargo ends: 09/07/2021

    Request copy

  • Figure 4a

    Final author's version, 612 KB, application/octet-stream

    Embargo ends: 09/07/2021

    Request copy

  • Figure 4B

    Final author's version, 612 KB, application/octet-stream

    Embargo ends: 09/07/2021

    Request copy

  • Figure 5a_revised

    Final author's version, 599 KB, application/octet-stream

    Embargo ends: 09/07/2021

    Request copy

  • Figure 5b

    Final author's version, 599 KB, application/octet-stream

    Embargo ends: 09/07/2021

    Request copy

  • Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM)

    Proof, 930 KB, PDF document

    Request copy

DOI

  • IRIDIUM trial investigators
  • Huib A M Kerstjens
  • Jorge Maspero
  • Kenneth R Chapman
  • Richard N van Zyl-Smit
  • Motoi Hosoe
  • Ana-Maria Tanase
  • Catherine Lavecchia
  • Abhijit Pethe
  • Xu Shu
  • Peter D'Andrea

Background: Patients with asthma who are inadequately controlled on inhaled corticosteroid–long-acting β2-adrenoceptor agonist (ICS–LABA) combinations might benefit from the addition of a long-acting muscarinic receptor antagonist. The aim of the IRIDIUM study was to assess the efficacy and safety of a once-daily, single-inhaler combination of mometasone furoate, indacaterol acetate, and glycopyrronium bromide (MF–IND–GLY) versus ICS–LABA in patients with inadequately controlled asthma. Methods: In this 52-week, double-blind, double-dummy, parallel-group, active-controlled phase 3 study, patients were recruited from 415 sites across 41 countries. Patients aged 18 to 75 years with symptomatic asthma despite treatment with medium-dose or high-dose ICS–LABA, at least one exacerbation in the previous year, and a percentage of predicted FEV1 of less than 80% were included. Enrolled patients were randomly assigned (1:1:1:1:1) via interactive response technology to receive medium-dose or high-dose MF–IND–GLY (80 μg, 150 μg, 50 μg; 160 μg, 150 μg, 50 μg) or MF–IND (160 μg, 150 μg; 320 μg, 150 μg) once daily via Breezhaler, or high-dose fluticasone–salmeterol (FLU–SAL; 500 μg, 50 μg) twice daily via Diskus. The primary outcome was change from baseline in trough FEV1 with MF–IND–GLY versus MF–IND at week 26 in patients in the full analysis set, analysed by means of a mixed model for repeated measures. Safety was assessed in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT02571777, and is completed. Findings: Between Dec 8, 2015, and Jun 14, 2019, 3092 of 4851 patients screened were randomly assigned (medium-dose MF–IND–GLY, n=620; high-dose MF–IND–GLY, n=619; medium-dose MF–IND, n=617; high-dose MF–IND, n=618; high-dose FLU–SAL, n=618). 2747 (88·8%) patients completed the 52-week treatment and 321 (10·4%) started but discontinued study treatment prematurely. Medium-dose MF–IND–GLY (treatment difference [Δ] 76 mL [95% CI 41–111]; p<0·001) and high-dose MF–IND–GLY (Δ 65 mL [31–99]; p<0·001) showed superior improvement in trough FEV1 versus corresponding doses of MF–IND at week 26. Improvements in trough FEV1 were greater for both medium-dose MF–IND–GLY (99 mL [64–133]; p<0·001) and high-dose MF–IND–GLY (119 mL [85–154]; p<0·001) than for high-dose FLU–SAL at week 26. Overall, the incidence of adverse events was balanced across the treatment groups. Seven deaths were reported (one with medium-dose MF–IND–GLY, two with high-dose MF–IND–GLY, and four with high-dose MF–IND) during the study; none of these deaths was considered by the investigators to be caused by study drugs or other study-related factors. Interpretation: Once-daily, single-inhaler MF–IND–GLY improved lung function versus ICS–LABA combinations (MF–IND and FLU–SAL) in patients with inadequately controlled asthma. The safety profile was similar across treatment groups. MF–IND–GLY therefore constitutes a good treatment option in these patients. Funding: Novartis Pharmaceuticals.

Original languageEnglish
Pages (from-to)1000-1012
Number of pages13
JournalThe Lancet. Respiratory Medicine
Volume8
Issue number10
Publication statusE-pub ahead of print - 9-Jul-2020

ID: 129390151